Thomas W. Dubensky - 03 Jan 2023 Form 4 Insider Report for Tempest Therapeutics, Inc. (TPST)

Reporting relationship: President, Director
Issuer ticker: TPST
Reported as of: 03 Jan 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jan 2023, 19:01:41 UTC
Prior SEC filing: 19 Aug 2022
Source filing: View source filing
Reporting owner signature: /s/ Stephen Brady, Attorney-in-Fact for Thomas W. Dubensky

Key filing fact

Thomas W. Dubensky filed Form 4 for Tempest Therapeutics, Inc. (TPST) on 05 Jan 2023.

Key facts

This page summarizes Thomas W. Dubensky's Form 4 filing for Tempest Therapeutics, Inc. (TPST).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 05 Jan 2023, 19:01.

Change

Previous filing in this sequence was filed on 19 Aug 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TPST transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +102,700
Change %
Price: $0.000000
Shares after: 102,700
Date: 03 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 102,700
Exercise price: $1.23
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

These stock options vest in a series of 48 equal monthly installments measured from January 3, 2023, subject to the reporting person's continued service.